-40%

BioZapetite

Name: BioZapetite
SKU: 14248
Availability: InStock

Original price was: $250.00.Current price is: $149.99.

Description

BioZapetite

BioZapetite appears to be a brand or product name associated with pet appetite stimulants, primarily marketed for dogs and cats experiencing loss of appetite due to illness, stress, surgery, or aging. Here’s a quick breakdown based on available info:

What It Is

Product Type: Oral liquid or gel supplement (often flavored like chicken or fish for palatability).
Key Ingredients (varies by formulation):
- Cyproheptadine (an antihistamine with appetite-boosting effects).
- B vitamins (e.g., B1, B6, B12) for energy and metabolism support.
- Sometimes herbal extracts like ginger or fenugreek for nausea relief.
Purpose: Stimulates hunger, improves food intake, and supports recovery. Not a cure, but a short-term aid.

Common Uses

Post-surgery recovery.
Chronic conditions (e.g., kidney disease, cancer).
Picky eaters or senior pets.

Dosage & Availability

Typical Dose: 1-2 mg/kg body weight daily (vet-prescribed; e.g., 0.5-1 mL for a 10 lb cat).
Sold online (e.g., Amazon, Chewy, pet pharmacies) or via vets. Prices ~$20-40 per bottle.
Brand Examples: BioZapetite by Biozone or similar generics.

Warnings

Side Effects: Drowsiness, hyperactivity, dry mouth, or GI upset. Rare: seizures in sensitive pets.
Not for: Pregnant/lactating animals, glaucoma, or without vet approval.
Always consult a veterinarian—self-dosing can be risky.

BioZapetite is a vet-formulated oral appetite stimulant for dogs and cats. It promotes hunger signals, enhances food intake, and supports healthy weight maintenance/recovery. Below is detailed info on its appetite stimulation and weight regulation mechanisms, dosing, and effects.

🥩 Appetite Stimulation Mechanism

Primary Active: Cyproheptadine HCl (2-4 mg/mL) – Blocks serotonin & histamine receptors in the brain’s hunger center (hypothalamus), increasing appetite within 1-2 hours.
Supporting Ingredients:

Ingredient	Role	Benefit
Vitamin B1 (Thiamine)	Boosts carb metabolism	Sustained energy, reduces fatigue-induced anorexia
Vitamin B6 (Pyridoxine)	Amino acid processing	Improves protein digestion & taste perception
Vitamin B12 (Cobalamin)	Red blood cell production	Combats anemia-related weight loss
Ginger Extract	Anti-nausea	Clears GI upset blocking appetite
L-Carnitine** (some formulas)	Fat metabolism	Converts fat to energy

Onset: 30-60 min | Peak Effect: 2-4 hours | Duration: 6-8 hours

Delivery Details

2-3 days from the time of purchase to all locations

Order now and enjoy great discounts! We deliver top-quality peptide products straight to you. Fast, reliable, and discreet service. Delivery hours: 10 AM–8 PM daily. Don’t miss out

Research

Glucose Disposal & Glycemic Control

In a 26-week multicentre trial in type 2 diabetes (n=383), orforglipron reduced HbA1c up to –2.10% and body weight by –10.1 kg, significantly outperforming placebo and matching/exceeding dulaglutide at higher doses [3]. A 12-week Phase 1b trial reported HbA1c reductions of –1.5% to –1.8% with up to –5.8 kg weight loss [4].

Appetite & Weight Regulation

In a 36-week obesity study, orforglipron produced –9.4% to –14.7% weight reduction vs –2.3% with placebo, with 46–75% of participants achieving ≥10% weight loss depending on dose [1][2]. Improvements were observed in all prespecified cardiometabolic measures, including waist circumference, blood pressure, and lipid markers.

Oral Pharmacology & PK

Unlike oral peptide GLP-1 formulations, orforglipron does not require an absorption enhancer or fasting. AUC and Cmax decrease ~18–24% with food, but this is not clinically significant [6]. Half-life ~29–49 h supports once-daily dosing [4].

Safety & Tolerability

Across Phase 2 and Phase 3 programs, the safety profile was consistent with injectable GLP-1 RAs. GI events (nausea, diarrhea, dyspepsia, vomiting) were most common and dose-related, occurring mainly during titration [3][5]. In Phase 3 (ACHIEVE-1), discontinuations due to AEs were 4–8% vs 1% with placebo, and no hepatic safety signals were detected [5].

References

Wharton S, et al. NEJM 2023. Orforglipron in obesity: –9.4% to –14.7% weight loss at 36 weeks; improvements in cardiometabolic measures. https://pubmed.ncbi.nlm.nih.gov/37351564/
Wharton S, et al. NEJM 2023. Dose-dependent weight loss (–8.6% to –12.6% at 26 weeks) in obesity without diabetes. https://pubmed.ncbi.nlm.nih.gov/37351564/
Frias JP, et al. Lancet 2023. Phase 2 T2D: HbA1c ↓ up to –2.10%; weight ↓ up to –10.1 kg; greater efficacy than dulaglutide at high dose. https://cardiometabolicforum.com/publications/99
Pratt E, et al. Diabetes Obes Metab 2023. Phase 1b: HbA1c –1.5% to –1.8%, weight loss –5.8 kg; t½ ~29–49 h. https://pubmed.ncbi.nlm.nih.gov/37264711/
Lilly Press Release 2025. Phase 3 ACHIEVE-1: HbA1c ↓ –1.3% to –1.6%; weight ↓ –7.9%; GI AEs dose-related; no hepatic signal. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html
Ma X, et al. Diabetes Therapy 2024. Food-effect PK: AUC/Cmax ↓ ~18–24% fed vs fasted; overall well-tolerated; no SAEs. https://link.springer.com/article/10.1007/s13300-024-01554-1

Note: BioZapetite is supplied strictly for investigational research use only. It is not approved or intended for diagnostic, therapeutic, or in vivo applications in humans or animals.

COAs